Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone. [PDF]
J Investig Med High Impact Case Rep, 2021 Butterfield JH.
europepmc +1 more source
Effects of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity [PDF]
, 2005 Lindsay Hawkins +2 more
openalex +1 more source
Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: A systematic review. [PDF]
Gastrointest TractMarucci MA, Lechner DW, Tafuto BA.
europepmc +1 more source
A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients. [PDF]
PLoS OneZeng L, Cheng X, Li J, Zhang J, Wu X.
europepmc +1 more source
Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients. [PDF]
Asian Pac J Cancer Prev, 2021 Annuar AA +7 more
europepmc +1 more source
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia [PDF]
, 2008 Stephanie J. Lee +32 more
openalex +1 more source
Peritoneal tuberculosis after imatinib therapy. [PDF]
, 2009 Kovacsovics, T. +3 more
core +1 more source
Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. [PDF]
Cancers (Basel)Boichuk S +3 more
europepmc +1 more source
Imatinib mesylate-induced kidney injury in the treatment of a gastrointestinal stromal tumor
, 2016 Kevin Zarrabi +2 more
openalex +2 more sources